title: Halo nevi association in nonsegmental vitiligo affects age at onset and depigmentation pattern.
abstract: OBJECTIVE
  To compare factors associated with halo nevi with nonsegmental vitiligo (NSV) vs NSV alone.
  
  
  METHODS
  Prospective observational study in 553 patients with a confirmed diagnosis of NSV attending a vitiligo clinic between January 1, 2006, and July 1, 2010.
  
  
  METHODS
  Vitiligo Clinic at the Department of Dermatology, University Hospital Center of Bordeaux, Bordeaux, France.
  
  
  METHODS
  The Vitiligo European Task Force questionnaire was informed for each patient attending the clinic with a confirmed diagnosis of NSV after the exclusion of other forms of vitiligo (focal, mucosal, and not classifiable). Thyroid function and antithyroid antibodies were screened if not obtained in the previous year.
  
  
  METHODS
  Extent of disease and markers of autoimmunity or autoinflammation.
  
  
  RESULTS
  Of the 553 patients, 130 had halo nevi-NSV and 423 had NSV. Family history of premature hair graying (odds ratio, 1.74; P < .01) was positively associated with halo nevi-NSV by univariate analysis. Using multivariate analysis, age at onset younger than 18 years, phototype, total body area, localization on the trunk, involvement of hands and feet, and total staging were found to be independent factors. Age at onset younger than 18 years; phototypes I, II, and III; trunk involvement; and staging were positively associated with halo nevi-NSV, whereas this association was negative for total affected area and involvement of hands and feet.
  
  
  CONCLUSIONS
  Halo nevi association in NSV affects age at onset and depigmentation pattern and has a stronger link with familial premature hair graying, suggesting that premature hair graying may involve, at least partly, an autoimmune pathway.
authors.affiliation: Department of Dermatology and National Reference Centre for Rare Skin Disorders, CHU St-André, 1, rue Jean Burguet 33075 Bordeaux, France. khaled.ezzedine@chu-bordeaux.fr
authors.forename: Khaled
authors.initials: K
authors.lastname: Ezzedine
authors.forename: Abou
authors.initials: A
authors.lastname: Diallo
authors.forename: Christine
authors.initials: C
authors.lastname: Léauté-Labrèze
authors.forename: Julien
authors.initials: J
authors.lastname: Seneschal
authors.forename: Djavad
authors.initials: D
authors.lastname: Mossalayi
authors.forename: Khalid
authors.initials: K
authors.lastname: AlGhamdi
authors.forename: Sorilla
authors.initials: S
authors.lastname: Prey
authors.forename: Serge
authors.initials: S
authors.lastname: Bouchtnei
authors.forename: Muriel
authors.initials: M
authors.lastname: Cario-André
authors.forename: Franck
authors.initials: F
authors.lastname: Boralevi
authors.forename: Thomas
authors.initials: T
authors.lastname: Jouary
authors.forename: Alain
authors.initials: A
authors.lastname: Taieb
mesh_terms: D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000368:Aged; D019588:Aging, Premature / Q000235:genetics; D015551:Autoimmunity; D002648:Child; D002675:Child, Preschool; D005260:Female; D006200:Hair Color / Q000235:genetics; D006801:Humans; D007223:Infant; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D055882:Nevus, Halo / Q000150:complications* / Q000453:epidemiology* / Q000473:pathology; D011446:Prospective Studies; D012720:Severity of Illness Index; D014820:Vitiligo / Q000150:complications* / Q000453:epidemiology* / Q000473:pathology; D055815:Young Adult